行情

PDSB

PDSB

PDS Biotechnology Corporation
NASDAQ

实时行情|Nasdaq Last Sale

2.510
-0.260
-9.39%
已收盘, 16:00 11/12 EST
开盘
2.670
昨收
2.770
最高
2.700
最低
2.410
成交量
5.52万
成交额
--
52周最高
17.00
52周最低
2.410
市值
1,450.49万
市盈率(TTM)
-1.0726
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

落后大盘

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PDSB 新闻

  • 全球商业信心降至2009年金融危机以来最低
  • 界面.1小时前
  • 美国人均喝奶量锐减 当地牛奶生产商申请破产保护
  • 界面.1小时前
  • 软银旗下电信子公司拟进行2018年上市来的首次发债
  • 新浪财经.1小时前
  • 脸书加码电子商务:推出支付工具FacebookPay
  • 澎湃新闻.1小时前

更多

所属板块

生物技术和医学研究
+0.45%
制药与医学研究
+0.31%

热门股票

名称
价格
涨跌幅

PDSB 简况

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
展开

Webull提供PDS Biotechnology Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。